Table 2. Proportions of First-line Drugs Prescribed Before and After Cabergoline and Pergolide Product Label Revisions for Valvulopathy Risk.
| Anti-Parkinson drugs | Pre-revision (n = 47) (%) | Post-revision (n = 367) (%) | P-value | ||
| Age, mean [SD] (years) (median, IQR)a | 57.5 [16.3] (56, 44–71) | 55.4 [13.7] (56 44–64) | |||
| Gender (men), N (%) | 20 | (42.6) | 178 | (48.5) | - |
| L-dopa | 20 | (42.6) | 155 | (42.2) | 0.967 |
| Ergot dopamine agonists | 8 | (17.0) | 42 | (11.4) | 0.269 |
| Cabergoline | 5 | (10.6) | 17 | (4.6) | 0.090c |
| Pergolide | 1 | (2.1) | 9 | (2.5) | 1.000c |
| Cabergoline or pergolide | 6 | (12.8) | 26 | (7.1) | 0.239c |
| Bromocriptine | 2 | (4.3) | 16 | (4.4) | 1.000c |
| Non-ergot dopamine agonists | 3 | (6.4) | 108 | (29.4) | <0.001 |
| Pramipexole | 3 | (6.4) | 84 | (22.9) | 0.009 |
| Ropinirole | 0 | (0) | 21 | (5.1) | 0.151c |
| Talipexole | 0 | (0) | 5 | (1.4) | 1.000c |
| Anticholinergics | 13 | (27.7) | 99 | (27.0) | 0.921 |
| Trihexyphenidyl | 8 | (17.0) | 69 | (18.8) | 0.768 |
| Biperiden | 5 | (10.6) | 28 | (7.6) | 0.404 |
| Other anticholinergicsb | 0 | (0) | 2 | (0.5) | - |
| Others | 9 | (19.1) | 88 | (24.0) | - |
| Selegiline | 2 | (4.3) | 19 | (5.2) | 1.000c |
| Amantadine | 5 | (10.6) | 58 | (15.8) | 0.378 |
| Entacapone | 0 | (0) | 13 | (3.5) | 0.378c |
| Droxidopa | 2 | (4.3) | 7 | (1.9) | 0.272c |
| Zonisamide | 0 | (0) | 0 | (0) | - |
“Pre-revision”: between July 2005 and March 2007. “Post-revision”: between April 2007 and December 2010.
a
Age when a first-line drug was prescribed.
b
Other anticholinergics include piroheptine, profenamine, and mazaticol.
Pearson's chi-square test was used to calculate P-values unless otherwise noted (P<0.002 after Bonferroni correction).
c
Fisher's exact test.